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Abstract
Background: Variant surface antigens (VSA) expressed on the surface of Plasmodium falciparum-infected red blood
cells constitute a key for parasite sequestration and immune evasion. In distinct malaria pathologies, such as
placental malaria, specific antibody response against VSA provides protection. This study investigated the antibody
response specifically directed against VSA expressed by parasites isolated from individuals presenting a given type
of clinical presentation.
Methods: Plasma and isolates were obtained from four groups of Beninese subjects: healthy adults, patients
presenting uncomplicated malaria (UM), cerebral malaria (CM), or pregnancy-associated malaria (PAM). The
reactivity of plasma samples from each clinical group was measured by flow cytometry against parasites isolated
from individuals from each clinical group.
Results: Antibody responses against VSAUM were predominant in CM, UM and HA plasmas. When analysed
according to age in all plasma groups, anti-VSACM and -VSAUM antibody levels were similar until six years of age. In
older groups (6-18 and >19 years of age), VSAUM antibody levels were higher than VSACM antibody levels (P = .01,
P = .0008, respectively). Mean MFI values, measured in all plasmas groups except the PAM plasmas, remained low
for anti-VSAPAM antibodies and did not vary with age. One month after infection the level of anti-VSA antibodies
able to recognize heterologous VSACM variants was increased in CM patients. In UM patients, antibody levels
directed against heterologous VSAUM were similar, both during the infection and one month later.
Conclusions: In conclusion, this study suggests the existence of serologically distinct VSACM and VSAUM.C M
isolates were shown to share common epitopes. Specific antibody response to VSAUM was predominant,
suggesting a relative low diversity of VSAUM in the study area.
Background
In areas of intense Plasmodium falciparum transmis-
sion, protective immunity to malaria is gradually
acquired during childhood, leading to decreased suscept-
ibility at adulthood. Immunological protection against
parasite blood stages is mainly antibody mediated [1,2].
Among protective antibodies are immunoglobulin G
antibodies with specificity for variant surface antigens
(VSA) expressed on the surface of P. falciparum-
infected red blood cells (IRBC) [3]. Their level of
expression increases with age, in relation to the endemi-
city of the area [4]. Clinical disease is thought to be the
consequence of infection by parasites expressing VSAs
that are not recognized by preexisting VSA-specific anti-
bodies in the infected individual. Each new parasite
infection induces a variant-specific antibody response,
with specificity for the VSA expressed by the infecting
parasite [4-6]. Unfortunately, an immense level of diver-
sity among the var genes was shown, although evidence
of geographic structuring of variation emerged in iso-
lates causing pregnancy-associated malaria (PAM) [7].
PAM mostly occurs in primigravidae, as they lack anti-
bodies against the particular variant parasite population
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VSAs [8,9]. Similarly, VSAs expressed by parasites iso-
lated from children presenting with severe disease
(VSASM) were described as more commonly recognized
than VSA expressed by parasites isolated from children
with uncomplicated malaria (VSAUM), suggesting that
distinct serological groups are related to the clinical sta-
tus of the infection [10-12].
VSAs contribute to the sequestration of IRBC in deep
organs via the binding to endothelial receptors. This
mechanism enables the parasites to avoid splenic clear-
ance [13]. In PAM, IRBC expressing VAR2CSA (the
major VSA specifically expressed by PAM parasites)
adhere to the placenta [14,15]. Severe malaria leads to a
wide range of clinical symptoms categorized in cerebral
malaria (CM), severe malarial anaemia, and respiratory
distress [16,17]. The pathophysiology of CM includes
cytoadherence of IRBC to endothelial cells, and the
accumulation of IRBC in brain capillaries was displayed
by electron microscopy [17,18]. The implication of
cytoadherence in the two other severe malaria types is
not so obvious, although the occurrence of mixed clini-
cal types of severe malaria is not rare. Our hypothesis
assumes that the clinical status of a malaria infection is
related to the specificity of the VSA expressed on the
IRBC. Although a limited number of studies have been
carried out to study antigenic variation in isolates
obtained in CM patients [11,19,20], VSACM,a sas u b -
group of VSASM, is likely to be relatively conserved due
to restricted functional specialization for high binding
capacities in brain capillaries. In the current study, the
antibody response specifically directed against VSA
expressed by parasites was investigated. Parasites were
isolated from a given type of clinical presentation, cere-
bral, uncomplicated, or pregnancy-associated malaria.
Methods
Study areas and patients enrolment
Patients were enrolled in Cotonou (6° 21’ 35’’ North, 2°
26’ 23’’ East) and Allada (6°39’52’’ North, 2°09’35’’ East)
in southern Benin over one malaria season (April to
September 2008). Allada is about 40 km north of Coto-
nou. In southern Benin, malaria is mesoendemic and
transmission is perennial (Damien et al., submitted).
The transmission level in Cotonou was characterized in
1992 by 33 infecting bites per man per year [21]. Severe
malaria mainly occurs during the rainy season (April to
mid-July). Cerebral malaria (CM) patients and pregnant
women were included in two health facilities in Coto-
nou, the National Hospital (CNHU, Centre national
hospitalo-universitaire) and the main maternity hospital
(HOMEL, hôpital mère-enfant de la lagune), respec-
tively. Uncomplicated malaria (UM) patients were
enrolled in two schools located at Allada in children
more than five years of age attending for school nur-
series. Healthy adults (HA) were recruited in the blood
donation centre in CNHU. All patients were included
after written informed consent from themselves or their
guardian. Patients were managed by the medical team of
each health facility. An adequate anti-malarial treatment
was administered according to the national malaria
treatment policy. Ethical clearance was obtained from
the Institutional Ethics Committee of the Faculté des
Sciences de la Santé att h eU n i v e r s i t éd ’Abomey-Calavi
in Benin.
Clinical and biological diagnostic
Three groups of patients presenting distinct clinical
malaria status were enrolled: uncomplicated malaria
(UM), cerebral malaria (CM) and pregnancy-associated
malaria (PAM). Briefly, UM was defined as the combi-
nation of fever (tympanic temperature ≥ 37.8°C) or a
history of fever in the preceding 24 hours, confirmed
presence of P. falciparum infection, and absence of any
severity sign as defined by the WHO [22]. CM was
defined by a Blantyre score at diagnosis ≤ 2c o m b i n e d
with a coma duration of six hours at least, and con-
firmed presence of P. falciparum infection with exclu-
sion of other cause for coma, particularly meningitis.
PAM cases were obtained in pregnant women just
before delivery. Patients were all screened for malaria
infection by rapid diagnostic test for P. falciparum
(Malaria Quick test, Cypress Diagnostics, Langdorp, Bel-
gique). A questionnaire was administered to the chil-
dren’ guardian, or the pregnant women to collect social
data, clinical signs and treatment received before hospi-
tal admission.
Two additional groups of subjects were added as
plasma controls, healthy male adults (HA) living in
Cotonou, and non-immune healthy French volunteers
(NI) living in France and having never been exposed to
malaria. Peripheral venous blood sample (5 ml) was col-
lected from all study individuals in vacutainer tubes
containing EDTA. Plasmodium falciparum infections
were confirmed by Giemsa-stained thick blood films,
and parasitaemia was quantified by counting against 200
leucocytes assuming a mean of 8,000 leucocytes per
millimeter of blood. Blood group was determined for
each blood sample. Plasmas were separated and frozen
from all subjects. Parasite isolates from all malaria-
infected patients with O blood group were frozen. Blood
count and lumbar puncture for meningitis diagnostic
were achieved for patients from the CM group.
Parasite isolates and in vitro maturation
Infected red blood cells obtained from patients with O
blood group were snap-frozen in a glycerolyte solution,
as described [23]. Twenty-six P. falciparum isolates
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and 12 in the UM group) were frozen at -150°C. Cryo-
preserved IE were subsequently thawed and matured in
vitro for 24-36 hrs [24]. The multiplicity of infection
(MOI) was estimated by PCR typing of the polymorphic
regions of the genes encoding merozoite surface pro-
tein-1 (msp1) and merozoite surface protein-2 (msp2),
as described previously [25]. The MOI was estimated as
the largest number of alleles observed between the two
loci analysis.
Plasma samples
A total of 256 plasma samples were collected as follows:
127 samples were collected at the time of malaria diag-
nosis (D0), 41 from CM patients, 62 from UM patients,
and 24 from women with PAM. CM and UM patients
were also seen at convalescence (D30), 17 plasma sam-
ples were obtained in the CM group, and 62 in the UM
group. The high number of lost to follow up in the CM
group is mainly explained by the urban localization of
the children enrolled, and the difficulty to get them
back one month after a severe malaria attack. Two sets
of control plasmas were obtained from 44 healthy adults
(HA) living in Cotonou, and from six French volunteers
never exposed to malaria (NI).
Typing of VSA expression by flow cytometry
The fluorescence-activated cell sorter (FACS) analysis was
used for measurement of specific anti-VSA antibody, as
described before [26]. Briefly, thawed parasites were
matured to late stages (late trophozoites and schizontes)
24-36 hrs at 37°C in a candle jar, and enriched by expo-
sure to a strong magnetic field (MACS, Miltenyi Biotec,
Paris, France). Aliquots of 2 × 10
5 IRBC in PBS-FCS 2%
were labeled with ethidium bromide (0.002 mg/ml) to
allow flow cytometric exclusion of remaining uninfected
erythrocytes, and with 100 μlo fg o a ta n t i - h u m a nI g G-
FITC (IM1627, Beckman Coulter, Nyon, Switzerland).
Labeled IRBC were sequentially exposed to 5 μl of plasma.
Samples were analysed from a minimum acquisition of
5,000 IRBC using a Facscalibur cytometer (Becton Dickin-
son). The level of IgG recognizing VSAs was expressed as
mean fluorescence intensity (MFI) in the channel for ethi-
dium bromide-labeled IRBC. Nonspecific labeling was
evaluated by analysis of uninfected (ethidium bromide-
negative) erythrocytes. All plasma samples tested against a
particular parasite isolate were processed and analysed in
a single assay. NI plasmas samples were tested against all
isolates. However, due to limitations in amounts of IRBC
available, not all plasma samples were tested against all
parasite isolates (Table 1). To be able to compare VSA
IgG levels between isolates and plasma samples, the mean
plus two standard deviations of log MFI values obtained
with the six NI samples was subtracted to all log MFI
values obtained with each isolate. The threshold for posi-
tivity was defined as two standard deviations above the
mean MFI from the six NI samples.
Statistical analysis
Data were analysed by using the Statview software pro-
gramme. For analyses performed with data obtained the
day of diagnosis, data obtained with homologous
plasma/isolate pairs were excluded. The levels of anti-
body responders were compared using the c
2 test. VSA
Ab recognition was evaluated by analysis of covariance
(ANCOVA), two-factor ANOVA, t-test and Wilcoxon
rank test for paired data. Clonality and msp family pre-
valence were compared between clinical groups by Krus-
kall-Wallis and Mann-Whitney U-tests. Spearman
correlation test was used to estimate MOI and parasite
density correlation. Values of P <0 . 0 5w e r ec o n s i d e r e d
statistically significant.
Results
Clinical and biological categorization of patients
A total of 127 malaria-patients were enrolled. Three
groups of patients were identified as CM (n = 41), UM
(n = 62), and PAM (n = 24) patients, as well as one
group of 34 malaria-exposed healthy male adults (HA).
CM patients were between six months and seven years
of age with a mean (± SD) of 3.3 (± 1.7) years. UM
patients were aged 9.3 (± 2.1) years, PAM women were
aged 24.9 (± 6.4) years, and HA were aged 35.1 (± 8.9)
years. In PAM women, gravidity varied between 1 and 5
(mean 1.9 ± 1.2), 13 were primigravidae (PG) and 11
were multigravidae (MG). Parasitaemia was highly
diverse between and within groups: CM, median (inter-
quartile range) of 32,653 (2,082 - 64,846) per μlo f
blood; UM, 3,555 (516 - 16,285)/μl; PAM, 17,391 (400 -
88,379)/μl. Mean tympanic temperature (± SD) at inclu-
sion was of 38.8 (± 1.2) for the CM patients, 37.2 (± .7)
in UM patients and 38.0 (± .9) in pregnant women.
Table 1 Number of isolate-plasma combinations analysed
by FACS.
Clinical type of isolate donors
Clinical type of plasma
donors
UM (n = 12) CM (n = 7) PAM (n = 7)
UM D0 (n = 62) 139 95 104
UM D30 (n = 62) 137 117 103
CM D0 (n = 41) 194 104 146
CM D30 (n = 17) 82 58 63
PAM (n = 24) 194 131 129
HA (n = 44) 183 120 134
UM, uncomplicated malaria; CM, cerebral malaria; PAM, pregnancy-associated
malaria;
HA, healthy adults; D0, Day of malaria diagnosis; D30, one month after
diagnosis.
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pital for at least two hours and presented a mean Blan-
tyre score (± SD) of 1.8 ± 0.46 (min. 0, max. 2). The
coma lasted 2.5 days on average (min. 1, max. 9).
Meningitis was excluded for all children. Anaemia char-
acterized the CM group with a mean haemoglobin level
of 6.6 g/L (± 1.5) and a mean hematocrit of 20.8 (± 4.5).
Erythrocytes count was low with 2.7 (± .6) T/L although
the mean globular volume and the mean haemoglobin
corpuscular content were normal. Respiratory distress
occurred in 4/39 (10.3%) children of the CM group.
Among the children suffering of CM, six died and five
came out of hospital without medical consent. At that
time among these five children, two presented a deep
coma, two a normal consciousness and the data was
missing for one.
The levels of clonality were similar whatever the clinical
origin of the isolates
Means (CI95%) for MOI were respectively 1.49 (0.6 -
3.6), 1.61 (0.6 - 3.1) and 1.83 (0.5 - 4.7) for CM, UM
and PAM isolates (P = .73 by Kruskall-Wallis test).
However, MOI increased with parasitaemia (P = .001,
r h o=. 3 0 7 ) .T h ep r e v a l e n c er a t e so ft h ea l l e l i cf a m i l i e s
for all isolates were 65%, 27% and 40% for the K1,
MAD20 and RO33 families of the msp1 locus, respec-
tively, and 94% and 7% for the 3D7 and FC27 families
of the msp2 locus, respectively. Interestingly, PAM iso-
lates presented a higher frequency for MAD20 and
FC27 alleles (48% and 23%, P =. 0 4a n dP = .009,
respectively), and a lower frequency for 3D7 alleles
(76.5%, P = .003) than other clinical groups of isolates.
RO33 alleles were more frequent in UM isolates than in
other groups (P = .05).
The level of anti-VSA antibody reactivity varies with the
clinical origin of the isolates tested
The levels of anti-VSA antibody responders were com-
pared against each type of isolates in plasmas of the dif-
ferent clinical groups of patients at the day of diagnosis.
Among CM, UM and HA plasma groups, these levels
were different between the three origins of isolates (see
Figure 1). CM and UM plasmas presented similar pat-
terns of anti-VSA responses. Both plasma types were
greater antibody responders against VSAUM than against
both VSACM and VSAPAM (P < .05 for all, P = .0006 for
VSAUM versus VSAPAM in UM plasmas). In HA plasmas,
antibody responses against VSAUM were higher than
VSAPAM. The primigravidae (PG) plasmas contained
similar antibody responses to the different VSA types. In
multigravidae (MG) plasmas, responses were higher to
VSAUM than to VSACM. The levels of anti-VSAPAM anti-
body responders in MG and PG plasmas were similar.
The quantitative results are also available (see Additional
file 1), showing all the specific parasite/plasma combina-
tions tested and including the non immune plasma used
as controls in the qualitative analysis.
Acquisition of anti-VSA antibodies with age varies with
the clinical origin of the isolates
The level of anti-VSA antibodies was analysed at differ-
ent ages in all plasma groups, except for anti-VSAPAM
Abs that were measured only in UM, CM, and HA plas-
mas (Figure 2). Anti-VSAUM antibodies levels remained
Figure 1 Levels of specific antibody responders to VSACM,V S A UM and VSAPAM. Antibody response was measured in different plasma
groups against heterologous P. falciparum isolates identified by their clinical origin. CM: cerebral malaria, UM: uncomplicated malaria, HA: healthy
adults, PG: primigravidae, MG: multigravidae. Groups were compared by c
2 test (** P < .005, * P < .05, ns. non significant).
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12. From that time, a plateau was reached and main-
tained until 54 with a mean MFI value around 3.5.
Overall, MFI levels for anti-VSAUM Abs increased with
age (ANCOVA, P < .0001). Anti-VSACM antibodies gra-
dually increased until 18 years then decreased, although
values did not vary statistically. Mean MFI values
remained low for anti-VSAPAM Abs (max. 1.5) and did
not vary with age. VSAUM and VSACM antibody levels
were then compared according to three age groups:
until 6 years old, between 6 and 18, older than 18. Until
6 years old, levels were similar (t-test). In both other age
groups, VSAUM antibody levels were higher than VSACM
antibody levels (P = .01, P = .0008, respectively).
Evolution of anti-VSAUM, and anti-VSACM IgG during the
first month after infection: the CM isolates share some
VSAs
First, MFI values obtained in plasma samples the day of
diagnosis and one month later were compared. Plasmas
from the same patients were tested against the isolate
infecting these patients. For UM plasmas and UM iso-
lates, 10 pairs of results were obtained with both D0
and D30 plasma samples for the homologous isolate. As
expected, the levels of anti-VSAUM antibodies had
increased at D30 (Wilcoxon rank test, P = .01). For CM
plasmas and CM isolates, only two pairs with both MFI
at D0 and D30 for the homologous isolate were avail-
able and both showed increased D30 values (see Table
2). Afterwards, the paired MFI values obtained at both
Day 0 and at Day 30 in UM or CM plasmas against all
UM or CM isolates, were compared, excluding homolo-
gous isolate-plasma pairs tested before (n = 125 UM,
n = 55 CM) (Figure 3). Interestingly, UM plasmas exhib-
ited similar levels of anti-VSAUM antibodies at D0 and
one month later (panel A), whereas CM plasmas exhib-
ited higher anti-VSACM antibodies levels at D30 (panel
C, P = .002). The same analysis was performed after
matching ages in UM and CM groups, i.e. with children
aged between five and seven years of age. Results were
Figure 2 Mean levels of anti-VSA IgG in Beninese plasma with age, according to the type of isolate tested. The adjacent table specifies
the number of different plasma donors, isolates and the total combinations tested for each age group by type of isolate. For UM and CM
isolates, the plasma included come from CM, UM, PAM patients and healthy adults. For PAM isolates, the plasma analysed do not include
plasmas from PAM women. Error bars indicate standard errors. Homologous samples are not included in the analysis.
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increased at D30 in the CM plasmas (P = .033), but not
in the UM plasmas (P = .206). The same type of analysis
was performed to test the potential cross-acquisition of
anti-VSACM by UM patients after an UM infection, as
well as anti-VSAUM by CM patients after a CM infec-
tion. No difference was obtained between the anti-
VSACM antibody levels displayed at D0 and D30 by UM
plasmas (panel B). Conversely, anti-VSAUM antibodies
were higher in CM plasmas at D30 than at D0 (panel D,
P = .05). These results show that infection with an iso-
late of the CM group induced the acquisition of antibo-
dies directed against other CM isolates, but also against
UM isolates. No such phenomenon was observed fol-
lowing infection with an isolate of the UM group.
Discussion
This study describes the levels of anti-VSA antibodies
displayed by plasmas from different clinical malaria sta-
tus, uncomplicated, cerebral, or pregnancy-associated
malaria, and from healthy adults. The study took place
in Benin where malaria transmission level is mesoen-
demic. Falciparum malariap r o t e c t i v ei m m u n i t yi s
acquired slowly, according to infections by new parasite
variants, until the repertoire of all parasite variants from
the area is recognized. Protective antibodies are partly
directed against parasite variant surface antigens (VSAs),
known to contribute to the cytoadherence of infected
erythrocytes to vascular endothelium. In CM and PAM,
cerebral capillaries and placenta respectively both con-
centrate preferentially the IRBC sequestration. In PAM,
the existence of a conserved adhesion phenotype in
selected parasite variants wasp r o v e n[ 1 4 , 1 5 ] .H o w e v e r ,
the existence of a specific type of variant surface anti-
gens for cerebral malaria was not shown.
This study includes patient groups categorized by their
malaria disease, uncomplicated, cerebral or associated to
pregnancy. As the transmission level of the study area is
mesoendemic and perennial, these patient classes were
also different in age, particularly the CM and younger
group. Consequently, anti-VSA antibody responses mea-
sured in the CM group were lower compared to the
other plasma groups, due to their lesser exposition to
malaria. Previous studies showed a more frequent recog-
nition of VSASM than VSAUM, and proposed the exis-
tence of rare and frequent falciparum variants [10,12].
In the present study, Figures 1 and 2 show inverse data.
VSAUM antibody responses were higher than VSACM
antibody responses, although acquisition of both anti-
Table 2 Plasma recognition of homologous infecting
isolate at D0 and D30 for all cases tested at both days.
Plasma type D0 MFI D30 MFI
UM* 1.0 2.17
UM 2.26 69.16
UM 1.01 1.71
UM 1.12 6.49
UM 1.44 2.33
UM 2.22 11.44
UM 1.14 1.12
UM 12.39 100.77
UM 1.44 2.83
UM 1.0 1.0
CM* 1.0 1.53
CM 4.76 5.07
Values are mean fluorescence intensities (MFI) measured by flow cytometry.
*UM: uncomplicated malaria, CM: cerebral malaria
Figure 3 Acquisition of VSA-specific IgG during the month following P. falciparum infection in plasmas samples from UM (n = 121)
and CM (n = 56) patients. UM (A, B) or CM (C, D) plasma samples were tested against P. falciparum isolates from UM patients (A, D) or from
CM patients (B, C). Centerlines indicate medians, boxes indicate the 25
th and 75
th percentiles of data points, bars indicate the 10
th and 90
th
percentiles and circles are outliers. Differences are derived from the Wilcoxon rank test for paired comparisons. ns means non significant.
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shown in Figure 2. After the age of 6, levels of anti-
VSAUM antibodies increased and reached higher levels
than anti-VSACM. A high anti-VSA antibody response
may reflect three options: i) VSA epitopes are conserved,
ii) VSA epitopes are highly prevalent in the area, or iii)
VSA epitopes are highly antig e n i c .T h ep r e v i o u s l yc i t e d
studies took place in Kenya and Ghana, where transmis-
sion intensity is much higher than in southern Benin.
These groups proposed that P. falciparum favours
VSASM variants presenting optimal binding ability.
However, whether high virulence is advantageous for
parasite population survival is questionable. Indeed, the
foundations of parasitism involve the search for equili-
brium between parasite and host, i.e. the survival of the
host to ensure long-term parasite proliferation. In our
understanding, the transmission level of the area allows
a certain level for parasite clonal diversity. The level of
anti-P. falciparum specific immunity certainly constitu-
tes another factor influencing the parasite clonal diver-
sity, as already suggested [27]. In the study area, the
prevalence of VSAUM antibody response compared to
VSACM may be explained by the balance between a rela-
tive conservation of VSAUM, or relative low clonal diver-
sity, and the level of immunity of the patient groups
tested. Epidemiological, entomological and socio-cultural
factors that are area-specific are also likely to interfere
with clonal composition of P. falciparum parasite
population.
Importantly, VSASM and VSAPAM are thought to be
more conserved than VSAUM, raising the hope for speci-
fic therapies targeting severe types of malaria. This
hypothesis can be argued as one month after infection
the level of anti-VSA antibodies able to recognize hetero-
logous VSACM variants had increased in CM patients
( F i g u r e3 ) .A l t h o u g ht h ei n c r e a s em a yb ed u et ot h ed i s -
ruption of immune complexes, this result shows that
VSACM share common epitopes. CM patients in the
study were younger than UM patients, and had been
probably less exposed to malaria. Consequently, if the
infecting isolate was encountered for the first time by
CM patients, the VSACM antibody levels logically
increased at D30, assuming that CM isolates share similar
VSA epitopes. In the UM group, the level of anti-VSAUM
did not increase one month after the initial infection.
These data show that the UM patients have already been
exposed to the different VSAUM and VSACM tested in the
experiment; it does not demonstrate that UM isolates do
not share epitopes. Interestingly, the plasmas tested one
month after CM infection also contained antibodies cap-
able to recognize VSAUM epitopes. Such result was
already described with plasmas sampled 28 days after a
SM infection [20]. This means that UM and CM isolates
s h a r es o m eV S A .T h ed a t am a ya l s ob ei n t e r p r e t e db y
saying that finally VSACM and VSAUM do not differ. As
the cellular immune response is known to have critical
consequences during CM [28], the local response of the
host could constitute the major element that decides
whether CM will develop or not in a non- or semi-
immune host. However, Figure 2 shows that the antibody
levels acquired with age differed according to the VSA
type tested. These data argue for the existence of serolo-
gically distinct VSACM and VSAUM. Ultimately, one
hypothesis derives from these findings. The prevalence of
isolates presenting VCACM may be low in the study area,
although they share common epitopes. On the contrary,
t h ep r e v a l e n c eo fV S A UM i s o l a t e sm a yb em u c hh i g h e r ,
and VSAUM may not be highly diverse, resulting in a high
antibody response specific to anti-VSAUM after the age of
six.
As expected, CM, UM and HA plasmas weakly recog-
nized VSAPAM isolates as shown in Figure 2. This is
explained by the rapid elimination of VSAPAM variants
by the spleen after delivery, once placenta is not present
anymore [29]. However, HA and UM plasmas were high
antibody responders for VSAPAM isolates (Figure 1).
These results suggest two hypothesis: i) PAM isolates
share common epitopes with non-PAM isolates; ii) their
presence in infecting isolates (before a rapid elimination)
allows a basal recognition in cytyometry experiments.
Additionally, the levels of antibody responses to VSA-
PAM detected in multigravidae plasmas were similar to
those measured in primigravidae plasmas. Like the low
anti-VSACM antibody response, this result is surprising
and suggests again a low prevalence for VSAPAM isolates
in the area.
Conclusion
In conclusion, this study suggests the existence of sero-
logically distinct VSACM and VSAUM. CM isolates were
shown to share common epitopes. Specific antibody
response to VSAUM was predominant, suggesting a rela-
tive low diversity of VSAUM in the study area.
Additional material
Additional file 1: Aubouy-figureSUPPL-MalariaJ-revised version.
Supplementary figure. Detailed relative levels of VSA specific IgG to
heterologous P. falciparum isolates according to the clinical origin of the
P. falciparum isolates, and to the plasma group. Each dot represents a
specific plasma/parasite combination. Figures show all combinations
tested with CM isolates (A1, A2), UM isolates (B1, B2, B3), and PAM
isolates (C1, C2). UM: uncomplicated malaria, CM: cerebral malaria, PAM:
pregnancy-associated malaria, PG: primigravidae, MG: multigravidae.
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